Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azimilide in ICD patients for reduction of cardiovascular hospitalizations or death
NL-OMON39164Phase 3Active, not recruiting
- Sponsor
- Forest Laboratories
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ventricular arrhythmia (VA) comparing Azimilide 75 mg once daily with Placebo once daily (2 arms). Primary endpoint: Time to first unplanned cardiovascular hospitalization, unplanned cardiovascular emergency department visit, or cardiovascular death. Started Mar 2013; status: active, not recruiting.
02
Drugs
azimilide
03
Conditions
ventricular arrhythmia (VA)
Beyond the preview
Go deeper on NL-OMON39164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39164.